X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

EXEL

Closed

Exelixis Inc

43.62
-0.46 (-1.04%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 44.075
Day's Range: 43.315 - 44.41
Send
When Written:
 
19.41
Exelixis Inc. is a biopharmaceutical company that focuses on the development and commercialization of therapies for the treatment of cancer. The company was founded in 1994 and is headquartered in Alameda, California.

Exelixis has developed several FDA-approved drugs, including Cabometyx (cabozantinib) for the treatment of kidney cancer and hepatocellular carcinoma, and Cometriq (cabozantinib) for the treatment of medullary thyroid cancer. The company is also developing other drugs for the treatment of various types of cancer, including prostate cancer, bladder cancer, and non-small cell lung cancer.

In addition to its drug development efforts, Exelixis has collaborations with other pharmaceutical companies to develop and commercialize drugs. The company has partnerships with Bristol Myers Squibb, Ipsen, and Takeda Pharmaceutical Company Limited.

Exelixis is publicly traded on the NASDAQ stock exchange under the ticker symbol "EXEL." As of June 2021, the company had a market capitalization of approximately $9.8 billion.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X